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Background: Monoclonal antibodies (mAbs) are essential tools in biological research, diagnosis and therapy, and
are conventionally produced in murine hybridoma cell lines. Professional applications of mAbs depend on the
steady supply of material. Because hybridoma cultures can stop producing the antibody or even die, preservation
of the unique epitope specificity of mAbs by rescue of the sequences encoding the antibody variable domains
(V regions) is important. The availability of these sequences enables not only the recombinant expression of the
original antibody for further applications, but opens the road for antibody engineering towards innovative
diagnostic or therapeutic applications. A time- and cost-efficient production system enabling the detailed analysis
of the antibodies is an essential requirement in this context.
Methods: Sequences were rescued from three hybridoma cell lines, subjected to sequence analysis, subcloned into
binary expression vectors and recombinantly expressed as chimeric mAb (constant regions of human IgG1:k1) in
Nicotiana benthamiana plants. The properties of the recombinant and the murine mAbs were compared using
competition enzyme-linked immunosorbent assay (ELISA) and surface plasmon resonance (SPR) spectroscopy. The
recognition of native PfMSP4 by the recombinant mAb was analysed by immunofluorescence staining of Pf 3D7A
schizonts and by western blot analysis of merozoite extract.
Results: The rescued sequences of all three hybridoma cell lines were identical. The recombinant mAb was
successfully expressed as IgG in plants at moderate levels (45 mg/kg fresh leaf weight). Preservation of the original
epitope was demonstrated in a competition ELISA, using recombinant mAb and the three murine mAbs.
EGF_PfMSP4-specific affinities were determined by SPR spectroscopy to 8 nM and 10 nM for the murine or
recombinant mAb, respectively. Binding to parasite PfMSP4 was confirmed in an immunofluorescence assay
showing a characteristic staining pattern and by western blot analysis using merozoite extract.
Conclusions: As demonstrated by the example of an EGF_PfMSP4-specific antibody, the described combination of
a simple and efficient hybridoma antibody cloning approach with the flexible, robust and cost-efficient transient
expression system suitable to rapidly produce mg-amounts of functional recombinant antibodies provides an attractive
method for the generation of mAbs and their derivatives as research tool, novel therapeutics or diagnostics.
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Monoclonal antibodies (mAbs) have become irreplaceable
for a wide variety of applications, including laboratory an-
alytics, diagnosis of chronic and infectious diseases as well
as targeted therapy [1]. All this was made possible by the
development of the hybridoma technology by Köhler and
Milstein in 1975 [2]. However, hybridoma cultures can be-
come unstable over time, and antibody expression declines
or ceases all together [3,4], meaning that the information
encoded in the variable regions (V regions) must be
rescued to preserve a given antibody’s unique epitope spe-
cificity and affinity. Based on the rescued V region infor-
mation various recombinant antibody formats can be
generated, including full-size recombinant (chimeric) anti-
bodies, minibodies, Fab fragments, and single-chain vari-
able fragments (scFv) [4,5]. In the field of malaria, most of
these formats have been introduced as potential thera-
peutic molecules [6]. Two predominant applications are
envisaged in this review: The development of bispecific
scFvs or Fab fragments for the recruitment of immune ef-
fector cells, or the generation of several mAb-isotypes
(IgG, IgA, IgM) to specifically modify effector functions.
This can only be facilitated through exact knowledge
of the sequence information. Furthermore, the V regions
can also be engineered, e.g., humanized by grafting the
complementarity determining regions (CDRs) onto suit-
able human variable domain framework regions (FWRs)
followed by affinity maturation, thus avoiding the draw-
backs of human anti-mouse immune responses in thera-
peutic applications [7]. To efficiently match the complete
variability of the V-region repertoire, many primer sets
used for their rescue contain nucleotide degeneracies or
consensus sequences [8-11]. In combination with mutations
that can occur during the inevitable PCR-amplification
steps, this can lead to deviations of the nucleotide-, and
eventually amino acid sequences between the parental and
the rescued antibody sequence. As a result changes or
losses of epitope specificity and/or affinity as well as insolu-
bility or extremely low expression levels have been observed
[12]. Careful analysis of the rescued V-region sequences
must be performed to identify and subsequently remove
such unwanted mutations. In many cases it will be impos-
sible to distinguish mutations accidentally introduced by
the rescue procedure from those occurring in mAbs as a re-
sult of affinity maturation. To verify the obtained se-
quences, the antibody has to be expressed recombinantly
and analysed for antigen binding in comparative assays in-
volving the parental murine mAb. For this purpose, transi-
ent expression of recombinant mAbs in plants is a cost-
efficient and robust method [13].
By the example of a murine mAb specific for the
Plasmodium falciparum merozoite surface protein 4
(PfMSP4), a workflow was developed, which allows the
rapid, inexpensive and accurate rescue and functionalconfirmation of V-region sequences. PfMSP4 is one of
several glycophosphatidylinositol (GPI)-anchored surface
proteins expressed at the merozoite stage and it has
been identified as a potential malaria vaccine, although
it has not reached clinical development. Nevertheless,
promising data have confirmed its protective role in
murine mouse models. Multiple studies have shown that
vaccination with a combination of MSP4 and MSP5 pro-
tects mice against both homologous and heterologous
challenge [14,15]. This work describes the hybridoma
antibody cloning of the heavy and kappa light chain
V-region sequences (VH/VL(κ)) of a novel murine anti-
body specific for the epidermal growth factor (EGF)-like
domain of PfMSP4 (EGF_PfMSP4), the cloning of the re-
spective V-region sequences into a plant expression vec-
tor containing a human IgG1 Fc or kappa1 domain, as
well as the transient expression in tobacco and detailed
characterization of the recombinant mAb.
Methods
Generation of monoclonal hybridoma cell lines specific
for EGF_PfMSP4
mE-ERH, a fusion protein comprising the EGF-like do-
mains of MSP1-19, MSP8 and MSP4 (Figure 1A,B,C),
was generated by genetic fusion of the corresponding
protein domains, cloning into pTRAkc-ERH, expression
as his-tagged and ER-retained protein by agroinfiltration
of Nicotiana benthamiana leaves and purification essen-
tially as described previously [16]. To determine the spe-
cificity of the raised antibodies, the EGF-like domains
were separately fused C-terminally to the red fluorescent
protein (DsRed) and expressed accordingly. Twenty-five
μg of purified mE-ERH was mixed with GERBU MM
and used for the immunization of BALB/c mice by one
prime and six consecutive boosts at a 14-day interval.
Hybridoma cell lines were finally generated by fusing
mouse myeloma cells (cell line Sp2/0-Ag14, obtained
from ATCC (CRL-1581)) to isolated spleen cells from
these mE-ERH-immunized BALB/c mice. The animal
experiments were approved by the Landesamt für Natur,
Umwelt und Verbraucherschutz Nordrhein-Westfalen
(LANUV), Germany, reference number 8.87.-51.05.30.10.077.
All animals received humane care according to the re-
quirements of the German Tierschutzgesetz, §8 Abs. 1
and the Guide for the Care and Use of Laboratory Ani-
mals published by the National Institutes of Health.
The screening ELISAs were performed by coating 50 ng
of antigen (mE-ERH or the single EGFs as DsRed-fusions).
After blocking with 5% skimmed milk, culture super-
natant was applied. Bound antibodies were detected by a
goat anti-mouse IgG (Fc-specific) conjugated to peroxid-
ase (PO) (Jackson Immuno Research, West Grove, PA,
USA) followed by visualization using ABTS (Roche,
Mannheim, Germany) according to the manufacturer’s
Figure 1 Generation of mE-ERH and isolation of EGF_PfMSP4-specific monoclonal hybridoma cell lines. (A) Expression cassette of the
pTRAkc_mE-ERH vector used for the expression of mE-ERH. The vector contains the Cauliflower mosaic virus 35S promoter (CaMV 35S promoter),
a 5′ UTR of the Chalcone synthase of Petroselium crispum (5′ UTR (Cs)), a signal peptide sequence followed by mE (the multi-EGF_MSP protein
as explained in (B) and (C)), which was inserted using NcoI/NotI restriction sites, a 6-fold histidine-tag for purification, an ER-retention signal and
the CaMV 35S terminator flank by scaffold attachment regions (SAR). (B) Components of the mE-ERH multidomain fusion protein. The protein
consists of the EGF-like domains of MSP1-19, both of MSP8, and MSP4. (C) Peptide-sequences of the EGF-like domains of the MSPs and corresponding
PlasmoDB accession numbers. (D) Reactivity of the parental polyclonal hybridoma cell line towards mE-ERH and its subdomains. The three selected
monoclonal hybridoma cell lines 2.48, 2.44 and 2.7 show exclusive reactivity towards EGF_PfMSP4.
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washed intensively with PBS-T between steps.
Primers and vectors
The outer primer set for the initial isolation of the V re-
gions (including V, D and J genes) was described by
Tiller et al. [8]. The VH amplification set consisted of
one forward primer to amplify all VH regions, which
anneals in the FWR1 of the VH region, thus accepting
partial mispriming, and one reverse primer for each im-
munoglobulin subtype, which binds in the constant do-
main. The VL(k) regions were amplified using primers
annealing in the leader peptide sequence and in the con-
stant domain. Therefore the entire VL region, including
V- and J-gene fragments, was readable after sequencing.
The pTRAkc-based [17] plant expression vectors,
pTRAkt_HC and pTRAkt_LC were used for plant expres-
sion of recombinant chimeric mouse-human IgG1. These
vectors contain the 5′ untranslated region (UTR) from
Tobacco etch virus (TEV) instead of the corresponding re-
gion of the Petroselinum crispum chalcone synthase found
in pTRAkc-mE-ERH. The expression cassette encodes amurine IgG leader sequence (GenBank ID DQ407610)
providing a signal peptide for secretion of the recombinant
protein, and harbouring the AgeI restriction site used for
the cloning of PCR-amplified V-region genes [8]. The
pTRAkt-HC and pTRAkt-LC vectors also include se-
quences encoding the human constant domain for the
heavy chain (hCγ1) allotype IgG1m17,1 (pTRAkt_HC) and
the light chain (hCκ1) allotype Km3 (pTRAkt_LC) [18], re-
spectively, featuring the SalI (pTRAkt_HC) and the BsiWI
(pTRAkt_LC) restriction sites for cloning.
RNA isolation, cDNA synthesis and DNA amplification
by PCR
Hybridoma cells were harvested and stored in RNA protect
cell reagent (Qiagen, Hilden, Germany). RNA was isolated
using the M&N NucleoSpin RNA II Kit (Macherey Nagel,
Düren, Germany). First strand cDNA was synthesized with
SuperScript® III reverse transcriptase (Invitrogen, Karlsruhe,
Germany) using oligo-dT primers. V regions were amplified
from this cDNA by PCR using the Expand High Fidelity
PCR system (Roche) essentially as previously described
although with only 30 amplification cycles [8]. All kits
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Sequence analysis, specific primer design and
V-region cloning
The PCR products of the VH and VL regions were
purified using the M&N NucleoSpin® Extract II Kit
(Macherey-Nagel) and sequenced on an ABI PRISM®
3730 Genetic Analyzer (Applied Biosystems, Carlsbad,
USA). Sequences were analysed using the IMGT/
V-quest [19,20] and NCBI nucleotide BLAST [21] on-
line tools. The FWR1 of the VH-gene sequence was
aligned to the most probable germ-line sequence, which
accordingly served as template for the design of a
FWR1-specific VH-region forward cloning primer. This
was necessary because the forward primer of the VH
region intends partial mispriming, as explained above.
Because the reverse VH and both VL(k) primers anneal
outside the V (D and J) regions, these were completely
readable. Therefore, the corresponding cloning primers
did not need sequence adjustment and could be directly
derived from the sequences. Primers were designed to
facilitate in-frame insertion of the amplified V regions
into pTRAkt_HC or pTRAkt_LC by AgeI and SalI for
the VH region, or AgeI and BsiWI for the VL(k) region,
respectively. After ligation, the plasmids were intro-
duced into Escherichia coli strain DH5α for cloning and
the sequences of isolated plasmids were confirmed as
described above.
Production of recombinant antibodies in plants
Full-length recombinant 2.44IgG1 was produced by infil-
trating Nicotiana benthamiana plants with Agrobacterium
tumefaciens strain GV3101 PMP90RK (GmR, KmR, RifR)
[22]. pTRAkt_2.44HC and pTRAkt_2.44LC were separ-
ately transformed into electrocompetent Agrobacterium
tumefaciens using a Multiporator (Eppendorf, Hamburg,
Germany). An additional Agrobacterium tumefaciens strain
containing pTRAkc-p19si [17] was used as a silencing
inhibitor [23]. All three clones were grown separately
and used for the infiltration of Nicotiana benthamiana
plants in a ratio of 2:2:1 for bacterial strains containing
pTRAkt_2.44HC, pTRAkt_2.44LC and pTRAkc_p19si,
respectively, as previously described [17].
After five days, leaves were harvested and shred in 3 ×
(v/w) ice-cold extraction buffer (PBS containing 10 mM
sodium disulphite, pH 8.0). The resulting extract was
prefiltered through Miracloth (EMD Millipore, Darmstadt,
Germany). A substantial fraction of contaminating plant
proteins was precipitated using 500 mM sodium chlor-
ide at pH 8.0 and incubated for 30 min at 4°C before
centrifugation at 38,000 × g for 20 min at 4°C. The
supernatant was filtered through a glass-fibre prefilter
(Sartorius Stedim, Goettingen, Germany) and a 0.45-μmfilter (cellulose acetate, Sartorius Stedim). The 2.44IgG1
antibody was finally purified by MabSelect™ chroma-
tography (GE Healthcare, Uppsala, Sweden) according
to the manufacturer’s recommendations, with 0.2 M
Tris–HCl (pH 9.0) as the binding and washing buffer,
and 0.2 M sodium citrate (pH 2.7) as the elution buffer.
Eluted mAbs were immediately neutralized using 1 M
Tris–HCl (pH 9.0), concentrated using concentrating
centrifugal devices (Vivaspin 30 kDa MWCO, Hydrosart
membrane, Sartorius Stedim) and stored in RPMI1640
containing 25 mM HEPES at −20°C.
Purification of murine IgGs from hybridoma culture
supernatants
The three hybridoma clones producing antibodies spe-
cific for MSP4 (2.44, 2.48, 2.7) were cultivated in ISF-1
medium (Biochrom, Berlin, Germany). The antibodies
were purified from 300 ml supernatant by MabSelect™
chromatography as described above.
Analysis of recombinant antibody function
ELISA and competition ELISA
The binding of recombinant 2.44IgG1 was assessed by
ELISA. Each well of a 96-well high-binding plate (Greiner
Bio-One, Frickenhausen, Germany) was coated with
100 ng of antigen in PBS and blocked with 2% BSA in
PBS. The IgGs were applied as 1:2 serial dilutions in dupli-
cate. Bound 2.44IgG1 was detected with goat anti-human
IgG (Fc-specific) conjugated to PO (Jackson Immuno Re-
search) and visualized with TMB (Invitrogen). The TMB
reaction was stopped with 1 M HCl after appropriate in-
cubation times at room temperature in the dark. Absorb-
ance was read at 450 nm.
Competition for antigen binding between 2.44IgG1 and
the three original murine IgGs was analysed by ELISA as
described above, but in this case 500 ng/ml 2.44IgG1 was
concurrently incubated on coated and blocked wells with
increasing concentrations of the murine IgGs in duplicate
and detected with goat anti-human IgG (Fc-specific) con-
jugated to PO (Jackson Immuno Research).
Immunofluorescence assay (IFA)
Antibody binding to MSP4 on cell membranes was ana-
lysed by immunofluorescence assay (IFA) as previously
described with minor modifications [17]. Pf 3D7A schiz-
onts from a permanent culture [24] were enriched by
Percoll (GE Healthcare) density centrifugation [25] and
allowed to mature into membrane-enclosed merozoites
by incubation in the presence of 10 μM E64 (Sigma-
Aldrich, Taufkirchen, Germany) [26]. IFAs were carried
out using methanol-fixed smears of these E64-treated
schizonts on SuperFrost microscope slides (Menzel,
Braunschweig, Germany). Schizonts were counterstained
with 50 μg/ml polyclonal rabbit anti-AMA1 (Ra-AMA1)
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Hoechst 33342 (Sigma-Aldrich). Ra-AMA1 was visualized
with goat anti-rabbit IgG conjugated to AlexaFluor®488 or
to AlexaFluor®594 (Dianova, Hamburg, Germany), the
murine 2.44IgG (50 μg/ml) was visualized with goat anti-
mouse IgG conjugated to AlexaFluor®488 (Invitrogen),
and recombinant 2.44IgG1 (50 μg/ml) was visualized with
goat anti-human IgG conjugated to Cy3 (Dianova). Slides
were mounted in ProLong Antifade Gold (Invitrogen) and
analysed using a Leica TCS SP8 Confocal Microscope
(Leica Microsystems, Wetzlar, Germany).
Western blot of merozoite extracts
Free merozoites were obtained by filtration of E64-treated
schizonts through a 1.2-μm Acrodisc syringe filter with
Versapor membrane (Pall, Dreieich, Germany) and were
frozen at −80°C at a concentration of 5 × 107 merozoites/ml.
After thawing, 600 μl of the suspension was centrifuged
at 16,000 x g for 6 min at room temperature, resus-
pended in 12 μl PBS, separated by SDS-PAGE under
non-reducing conditions and blotted onto a nitrocellulose
membrane. The blot membrane was blocked with 2%
non-fat milk powder in PBS and incubated for one hour
with 4 μg 2.44IgG1. The latter was visualized with a goat
anti-human IgG (H + L-specific) antibody conjugated to
AP (Promega, Mannheim, Germany). The membrane was
washed three times for 10 min in PBS with 0.1% Tween-
20 between steps and the signal was detected using NBT/
BCIP (Roth, Karlsruhe, Germany).
Surface plasmon resonance (SPR) spectroscopy
The binding of murine and recombinant derivatives of
mAb 2.44 was investigated by SPR spectroscopy using a
Biacore T200 instrument (Biacore, GE Healthcare) and
CM5-S-Series sensor chips. These were either functional-
ized in one of two ways: (i) with recombinant Protein A
(Sigma-Aldrich) immobilized onto flow cell 2 (Fc-2) by
EDC/NHS coupling with 12-min activation/deactivation
and 20-min contact time, 250 μg/ml protein A in 10 mM
sodium acetate pH 4.25, Rimmob = 4,600 RU, Fc-1 reference
EDC/NHS coupling with 12-min activation/deactivation,
or, (ii) with the appropriate reagent from the Mouse Anti-
body Capture Kit (RaM-Fc, Biacore, GE Healthcare)
immobilized onto flow cell 4 (Fc-4) by EDC/NHS coupling
with 12-min activation/deactivation and 20-min contact
time, 50 μg/ml Ram-Fc in 10 mM sodium acetate pH 5.1,
Rimmob = 11,000 RU, Fc-3 reference EDC/NHS coupling
with 12-min activation/deactivation. Between measure-
ments, the surface was regenerated by pulsing for 1 min
with 30 mM HCl. Fc-1 and Fc-3 were used as references
for blank subtraction.
For kinetic analysis, 320–350 RU of the antibody vari-
ants (recombinant and murine 2.44) were captured onto
immobilized Protein A or RaM-Fc, respectively, and mE-ERH was injected at different concentrations (275 nM ser-
ial 1:3 dilution to 3.4 nM) at a flow rate of 30 μl/min for
180 sec. Dissociation was followed for 450 sec. Between
measurements, the surface was regenerated by pulsing
for 1 min with 30 mM HCl. Buffer injections were used
for double referencing. All measurements were taken at
25°C using HBS-EP (10 mM HEPES, 150 mM NaCl,
3 mM EDTA, 0.005% Tween-20) as the running buffer.
Binding curves were evaluated using Biacore T200
Evaluation Software (GE Healthcare).
Results
Selection of monoclonal hybridoma cell lines
One polyclonal hybridoma cell line was isolated, showing
specificity towards mE-ERH, more specifically towards
EGF_PfMSP4. After limiting dilution, three monoclonal
hybridoma cell lines specific for EGF_PfMSP4 (2.48, 2.44
and 2.7) were selected (Figure 1D), derived from the poly-
clonal clone with proven specificity for EGF_PfMSP4.
V-region rescue and sequence identification
Total RNA was isolated from the three selected
EGF_PfMSP4-specific hybridoma clones, and first-strand
cDNA synthesized using oligo-dT primers was used for
the specific amplification of V regions. Sequence analysis
revealed one unique antibody sequence from all three
hybridoma clones, bearing VH and the VL sequences allo-
cated to subtypes VH3 and VL(k)4. As expected, mutations
relative to germ-line sequences were predominantly found
within the CDRs and were less prevalent in the FWRs
(Figure 2). Unfortunately, the primer set not only ampli-
fied the specific PCR product, but also the aberrant Igκ
pseudogene from the myeloma SP2/0 cells (using primer
5′L-Vk-3 [8]) but this known sequence [28] was easily
identified using NCBI nucleotide BLAST. The functional
VH region was thus amplified using the primers 5′-AAC
AAC ACC GGT GTA CAT TCC GAT GTG CAG CTT
CAG GAG TCG GG-3′ and 5′-GTT GTT GTC GAC
GCT GAG GAG ACG GTG ACC GTG GTC CC-3′. Ac-
cordingly, the functional VL(κ) sequence was amplified
using the primers 5′-AAC TGC AAC CGG TGT ACA
TTC CGA AAT TGT CCT CAC CCA GTC TCC-3′ and
5′-GTT GTT CGTACG TTT TAT TTC CAA CTT TGT
CCC C-3′.
Cloning, expression and binding analysis of recombinant
2.44IgG1
The V regions were transferred into the respective
pTRAkt expression vectors (Figure 3A) and introduced
into electrocompetent Agrobacterium tumefaciens, which
were subsequently used for the infiltration of Nicotiana
benthamiana plants. Following transient expression,
the recombinant 2.44IgG1 was successfully purified by
MabSelect™ chromatography, yielding 45 mg of antibody
Figure 2 Sequence alignment of the rescued antibody sequence and the corresponding germ-line sequence. Antibody V regions were
amplified from cDNA isolated from the hybridoma cell line 2.44 using specific primers for the VH and VL regions. The protein-sequence alignment
included the most closely related germ-line V gene indicated by the IMGT/V-quest tool. For both, the VH (A) and VL (B) domains, CDRs 1–3 were
determined according to Kabat definitions [51] and are highlighted in boxes.
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mE-ERH was confirmed by ELISA (Figure 3C). Specific
antigen binding, defined as > three-fold background ab-
sorbance at 450 nm (0.045 units), was detectable at anti-
body concentrations as low as 8 ng/ml. Using this setup,Figure 3 Generation and characterization of recombinant 2.44IgG1. (A
contain the CaMV 35S promoter , a 5′ UTR of the TEV (5′ UTR (TEV)) and a m
constructed, one containing the genetic information for the hCγ1 sequence
sequence (pTRAkt_LC). The rescued VH and VL regions were inserted using
assembly of recombinant 2.44IgG1. Recombinant 2.44IgG1 was purified fro
of purified 2.44IgG1 was analysed for purity and correct antibody assembly
reducing (r) conditions. (C) Recognition of mE-ERH by recombinant 2.44IgG
by ELISA using 100 ng mE-ERH per well. Recombinant 2.44IgG1 was probe
was stopped with 1 M HCl. (D) Competition of recombinant 2.44IgG1 by pare
antibody and the three murine antibodies, a competition ELISA was carried o
and increasing concentrations of the murine antibodies. Recombinant 2.44IgG
reaction was stopped with 1 M HCl.saturation of the antibody occurred at a concentration of
500 ng/ml.
A competition ELISA was used to compare the epitope
of the initial hybridoma antibodies and the recombinant
derivative. Antigen binding was equally inhibited by all) Expression cassette of pTRAkt_HC and pTRAkt_LC. The vectors
urine IgG signal sequence targeting the apoplast Two vectors were
(pTRAkt_HC) and one containing the genetic information for the hCκ1
the AgeI/SalI (VH) or AgeI/BsiWI (VL) restriction sites. (B) Purity and
m filtered plant extract by MabSelectTM chromatography, and 2 μg
by SDS-PAGE (12% polyacrylamide) under non-reducing (nr) and
1. The antigen-binding activity of recombinant 2.44IgG1 was analysed
d with goat anti-human IgGFc
PO, visualized with TMB whose reaction
ntal murine IgGs. To compare the binding activity of the recombinant
ut using a constant concentration of 500 ng/ml recombinant 2.44IgG1
1 was probed with goat anti-human IgGFc
PO, visualized with TMB whose
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these three clones (Figure 3D). The affinities of the mur-
ine and recombinant antibodies were determined by SPR
spectroscopy, revealing similar affinity constants (KD) of
8 nM (±0.15 nM) and 10 nM (±0.01 nM) for the paren-
tal murine antibody and the recombinant antibody, re-
spectively (Table 1).
Detection of native PfSMP4 by murine and
recombinant 2.44IgG1
IFAs using synchronous Pf 3D7A parasites were per-
formed to test the ability of antibodies to bind to the
GPI-anchored MSP4 protein, which is homogenously
distributed on the merozoite surface. The immunofluor-
escence signal confirmed the staining of merozoite sur-
face proteins at the late schizont stage (Figure 4A and B),
similar to the AMA1 staining pattern at this stage. IFAs
using the murine antibody and the recombinant antibody
showed the same staining pattern. Unspecific binding
to other MSPs was excluded by the detection of a single
40-kDa band in merozoite extracts by western blot, cor-
responding to the anticipated molecular size of MSP4
(Figure 4C) [29].
Discussion
The here-applied strategy for the rapid and accurate res-
cue of V-region sequences was adapted to the strategy
which was introduced by Tiller et al. [8,30]. Major alter-
ations in the method presented in this work are the de-
sign of the VH-region forward primer, the introduction
of Nicotiana benthamiana as the expression host and
the application of analytical methods, which are of es-
sential importance for the characterization of antibodies
specific for P. falciparum. A mouse (V region)-human
(Fc region) chimeric mAb was generated instead of re-
constituting a murine full size IgG, because these par-
tially humanized antibodies are usable in other assays
investigating the cellular participation in the antimalarial
immune response, such as ADCI or ADRB [31,32].
The combination of these methods is suitable for rou-
tine use in any laboratory familiar with hybridoma cell
lines, and can be used to eliminate the risk of losing
the genetic information of unique antibodies. V-region
rescue and sequence analysis is helpful to avoid workingTable 1 Affinities of the murine and the recombinant
2.44IgG1 mAb determined by SPR spectroscopy
Antibody ka (SE) [1/Ms] kd (SE) [1/s] KD (SE) [M]












ka = association constant; kd = dissociation constant;
KD = affinity constant = kd/ka.
SE = standard error.with apparently different clones producing identical mAbs
as a result of clone proliferation during the limiting dilu-
tion steps used in the hybridoma generation [33]. Amplify-
ing the V regions of antibodies starting off with mRNA
isolation from hybridoma cells can be a labour-intensive
process, but the here-used method reduces the workload
to a minimum while ensuring that V-region sequences are
rescued with high efficiency and accuracy, because as re-
ported by Tiller et al., the primer set achieves ~60% rescue
efficiency in a single cell PCR method, and all highly abun-
dant V-gene families are amplified [8]. Therefore, it can be
expected that the rescue efficiency based on cDNA from a
larger amount of cells will be significantly higher.
In contrast to other primer sets that are entirely based
on primers containing degenerate and/or consensus posi-
tions, the here-used primer set reduces the risk of primer-
derived mutations to a minimum since only the consensus
forward primer of the VH region contains such sequence
ambiguity. Sequence mutations have to be avoided, be-
cause even one single substitution within antibody FWRs
may reduce or even completely abolish antigen binding
[34]. De Haard et al. identified residue 6 (FWR1) of the
VH region as one of the most crucial residues for correct
antibody folding and thus antigen recognition. It is, there-
fore, important to verify that the rescued sequence truly
represents genetic information that determines the affinity
of the corresponding antibody. An alternative approach to
confirm the rescued VH-sequence is the use of degenerate
primers in combination with N-terminal peptide sequen-
cing of the original murine antibody [35]. This method is
feasible, but more expensive and often not directly avail-
able. Therefore, the rescued sequence information was
analysed by comparison with the open-access online data-
base IMGT, but also here alternatives are available such
as VBASE2 and NCBI [20,36,37]. All of these have as-
sembled comprehensive antibody germ-line sequence
data. VH-FWR1 residues could be verified to match the
corresponding germ-line sequence, which generally pro-
vides the best guess regarding the respective residue. Al-
though that at least in the human system VH-FWR1
mutations can occur in heavily affinity matured antibodies
even at the highly conserved position 6, the VH-FWR1
region is the region which seems to be moderately affected
by somatic hypermutation when compared to other regions
[38,39]. Additionally to the here-presented EGF_PfMSP4-
specific antibody, this technique was successfully applied
to rescue V-region sequences from several anti-malarial
murine mAbs, including mAbs against AMA1, MSP3 and
HRP2 (unpublished data).
Furthermore, the rescued sequences can be used to
generate any recombinant antibody format, including
scFv, Fab, F(ab)2 and full-size antibodies featuring Fc-
regions of the required species and isotype. Even though
these formats can be generated more quickly if the
Figure 4 Detection of native PfMSP4 by recombinant 2.44IgG1. (A) Specific binding of the murine 2.44IgG1 to methanol-fixed Pf 3D7A
schizonts was assessed by IFA. The murine 2.44IgG1 was visualized with AlexaFluor®488-conjugated goat anti-mouse IgG secondary antibody
(green) and AMA1 on the parasite surface was stained with Ra-AMA1 which was visualized with AlexaFluor®594 conjugated secondary antibody
(red), showing the circular localization of AMA1 in mature schizonts. Nuclei were stained with Hoechst 33342 (blue). The overlay image includes
the bright field image. The small overlay shows the lack of green staining obtained with an irrelevant murine IgG. Scale bar = 2.5 μm. (B) AMA1
on the parasite surface was stained with Ra-AMA1 and visualized with AlexaFluor®488-conjugated secondary antibody (green), showing a circular
localization of AMA1 indicating fully mature schizonts. The recombinant 2.44IgG1 was visualized with a Cy3-conjugated goat anti-human IgG
secondary antibody (red). Nuclei were stained with Hoechst 33342 (blue). The overlay image includes the bright field image. The small overlay
shows the lack of red staining obtained with an irrelevant chimeric IgG. Scale bar = 2.5 μm. (C) Detection of PfMSP4 by recombinant 2.44IgG1
using western blot analysis. A western blot of SDS-PAGE-separated merozoite extract was probed with 4 μg of the recombinant 2.44IgG1
revealing one specific band (~40 kDa), indicated with an arrow, which corresponds to the anticipated molecular size of PfMSP4.
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analyses is omitted, but the results may be less satisfactory,
since uncorrected primer-derived mutations may lead to
loss of epitope-specificity and affinity as well as problems
with expression yields and solubility [12]. The analysis
of recombinant mAbs based on the rescued V regions
circumvents these drawbacks by allowing the direct com-
parison of the antigen-binding properties of the rescued
antibody and its original hybridoma-produced counter-
part. Additionally, the recombinant format of the antibody
allows a completely new therapeutic approach in the mal-
aria field, anti-malarial antibody fusion proteins. In such
an antibody fusion protein, an scFv is genetically fused to
a protein with anti-malarial activity. The resulting protein
has a significantly increased activity and therefore meets
the criteria for a potential therapeutic agent [40].
The here-applied plant-based transient expression of a
mouse-human chimeric full-size antibody has been shown
to yield a functional mAb at reduced costs and saved time
[41]. V-region sequences can be cloned into appropriate
vectors, expressed transiently in Nicotiana benthamiana
by agro-infiltration and purified within two to three
weeks after sequence rescue and analysis, in this case yiel-
ding >40 mg/kg of pure full-size IgGs with similar binding
characteristics as shown by SPR spectroscopy analysis.
In mammalian expression systems, very high yields are
only achieved after cost- and time-consuming cell line
development and carefully regulated cultivation of cells
[42]. Furthermore, the agro-infiltration-based transientplant expression system provides the opportunity to easily
express different recombinant proteins (e.g., heavy and
light chains of antibodies) simultaneously by co-infiltration.
Different leaves of the same plant can be used to efficiently
compare independent mAbs as well as different combina-
tions of antibody heavy and light chains or mutants
thereof, making this system ideally suited for the time-
efficient production and analysis of antibody sequences de-
rived from a hybridoma antibody cloning approach.
In the context of malaria research, antibodies can be
used for the functional analysis of potential vaccine tar-
gets, as well as therapeutic molecules. Besides the deter-
mination of epitopes and antigen-binding characteristics,
the analysis of parasite growth inhibitory efficacy in vari-
ous in vitro assays, including the blood-stage growth in-
hibition assay (GIA), transmission blocking assays (TBA)
or the inhibition of sporozoite invasion (ISI), is essential
to asses the suitability of a mAb for the desired applica-
tion. Therefore it is beneficial if the mAbs can be effi-
ciently produced at mg quantities at low cost in one single
batch to facilitate the concurrent screening of several
mAbs with potential for the desired downstream applica-
tion. The purified recombinant mAb can directly be com-
pared with the parental murine antibody by appropriate
analytical methods like competition ELISA and/or SPR
spectroscopy-based affinity determination, to confirm the
rescue of the correct V regions and thus avoid loss of the
antibody if the original hybridoma cell line becomes un-
stable or dies off.
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objective of further investigations besides blocking activ-
ity of the mAb, as it is the case in GIAs, TBAs and ISIs,
several aspects still need to be considered. It has been
shown that murine mAbs were successful in protecting
mice against parasite-challenge, but their corresponding
chimeric mAbs (bearing human Fc regions) were not
[43]. In contrast, when mice were transfected with the
human receptor I for IgG (FcγRI, CD64), fully human
mAbs derived from semi-immune Gambian adults were
able to control parasitemia [44]. This indicates the im-
portance of the IgG-Fc region for protection in its par-
ental species. For human applications, fully human
mAbs have the significant advantage of not inducing any
human anti-mouse immune responses, like fully murine,
and also mouse-human chimeric mAbs do, as intro-
duced in the background section. Therefore, a homolo-
gous workflow for the generation of fully human
antibodies is currently being set up at the Fraunhofer-
Institute for Molecular Biology and Applied Ecology
IME (Aachen, Germany) [45].
At this point, it has to be mentioned that the IgG-Fc
N-glycan profile essentially contributes to FcγR engage-
ment [46], which is crucial for the effector cell recruit-
ment in vivo and similarly for the respective assays
in vitro (ADCI, ADRB). Plant-derived mAbs bear a dis-
tinct IgG-Fc N-glycan profile, and especially the plant-
specific β1-2 xylose located at the bisecting mannose has
been shown to interfere with binding to IgG-FcRs (FcγRs)
[47]. If these applications are finally striven for, either a
mammalian expression system may be chosen, or genetic-
ally modified plants which attach a humanized IgG-Fc
N-glycan profile. The knockdown of the xylosetransferase-
gene has been shown to restore binding of a plant-derived
mAb to its FcγR [47].
It has recently been discussed, whether plant-derived
mAbs are applicable acute-phase drugs, especially against
the viral disease Ebola, one of the major acute burdens in
Western Africa [48,49]. The major obstacle here is the im-
pressively large scale of ~100 kg plant material to yield
one complete dose (10.5 g) for human application [48].
One licensed therapeutic antibody against CD20-positive
lymphoma, rituximab, requires an annual dose of ~1.8 g
per patient [50], somewhat similar to the estimated dose
required to efficiently control parasitemia in FcγRI-
transgenic mice [44] (1.5 mg mAb/mouse, adding up
to ~2.6 g per human of 70 kg, resulting in 25 kg plant
material, given an expression rate of 100 mg mAb/kg
fresh leaf weight, according to the calculations by
Rybicki [48]). Finally, the work here describes a simple
and fast work flow for the initial screening of a mAb’s
characteristics and functionality. Indisputable, there is
still many research to be done to meet the criteria for a
cost-efficient production of a final, especially mAb-based, therapeutic against poverty-related diseases, such
as ebola, or malaria.
Conclusions
Antibody V-region rescue is an essential technique to pre-
serve the unique epitope binding specificity of mAbs. Here,
an efficient combination of methods for the rescue and
transient plant-based expression of murine antibody se-
quences is presented, using an EGF_PfMSP4-specific anti-
body as an example. The complete workflow is described
in detail, including initial V-region amplification, cloning,
heterologous expression in Nicotiana benthamiana and
verification of the rescued sequences by comparative func-
tional analyses. The described method can be applied to fa-
cilitate the rescue, production and characterization of
larger numbers of monoclonal antibodies. This is especially
relevant in the field of malaria research where the plurality
of P. falciparum proteins makes it necessary for investiga-
tors to create their own specific mAbs for analytical pur-
poses, to investigate new vaccine targets or as starting
point for antibody-based therapeutics.
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